New Frontiers for Progress: Catalyzing Breakthroughs

Thank you to everyone who joined us in Amsterdam on Saturday, 27 September 2025 for our 4th annual OSIC Member Meeting & AI/Biomarker Innovation Showcase.

 

This year’s meeting was chaired by Dr. Kevin Brown, National Jewish Health, and was a day filled with bold ideas, breakthrough thinking, insightful presentations and collaborative discussions – all focused on shaping the future of lung disease research.

 

The agenda highlighted key opportunities for progress — from bronchiectasis as a promising new therapeutic frontier to advancing sarcoidosis understanding through global registries and AI. Attendees learned about innovative imaging techniques like Optical Coherence Tomography (OCT) and gained insights from world-leading experts in generative AI, predictive modeling, and interpretability. The event closed with inspiring success stories from OSIC members who are turning data into discovery.

Agenda

  • Saturday 27 September 2025 ​

    11:45 a.m. – 4:00 p.m.
    11:45 – 16:00 (CEST)

  • Lunch Buffet

    5th Floor Restaurant
    11:45 a.m. – 12:15 p.m.

  • Member Meeting

    6th Floor
    12:30 p.m. – 4:00 p.m.
    12:30 – 16:00 (CEST)

Bronchiectasis: A New Therapeutic Frontier
From Orphan Finding to Frontline Target

  • Panelists
Dr. Kevin Brown
Dr. Kevin Brown Chair, Department of Medicine
National Jewish Health (NJH)
Pulmonology Lead, OSIC
Dr. Helmut Prosch
Dr. Helmut Prosch Department of Biomedical Imaging and Image-guided Therapy
Medical University of Vienna
Prof. Luca Richeldi
Prof. Luca Richeldi Complex Operational Unit of Pulmonology
Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart
  • Discussion Points
  • Rising Global Prevalence & Burden: Why bronchiectasis is increasingly being recognized as a significant public health issue because of unmet need and the decline in quality of life

  • Phenotyping & Endotyping Advances: Connecting imaging features with clinical subgroups to enable precision medicine approaches

  • Overlap with Other Diseases: When bronchiectasis coexists with COPD, asthma, ILD, or post-infectious fibrosis

  • AI & Quantification Opportunities: Automating airway measurements, mucus plugging scoring, and progression tracking

  • Collaboration Call-to-Action: How OSIC members (pharma, machine learners, clinicians) can build a shared bronchiectasis resource

Sarcoidosis: From Complexity to Clarity?

  • Presenter
Elise Hoover
Elise Hoover Vice President of Research
Foundation for Sarcoidosis Research (FSR)
  • Discussion Points
  • The Challenge: Sarcoidosis is complex, heterogeneous, and historically understudied.

  • FSR’s Leadership: U.S. patient registry and partnership with OSIC; international registry planned for the future

  • AI/ML Opportunities: Predicting progression, phenotyping multi-organ involvement, identifying novel biomarkers

  • Engagement Opportunity: Inviting pharma and researchers to collaborate on future sarcoid AI initiatives

Beyond CT: How Optical Coherence Tomography Unlocks Microstructural Insight into Fibrosis

  • Presenter
Dr. Lida Hariri
Dr. Lida Hariri Associate Professor of Pathology
Massachusetts General Hospital (MGH)
  • Discussion Points
  • Visualize healthy and diseased airway and lung microstructure in vivo over large volumes (as a form of vivo microscopy)

  • Diagnose early lung disease at a microscopic level without needing invasive surgical biopsies

  • Quantitatively measure changes over disease progression and therapy on a microscopic level

  • Provide rich, quantitative data that could feed AI models for disease phenotyping and outcome prediction

  • Can be used to diagnose and characterize many lung diseases, including fibrotic ILDs, COPD, small airways disease, bronchiectasis, and post-COVID fibrosis

Showcase Presentation: Generative AI in Action

  • Presenter
Prof. David Barber
Prof. David Barber Global leader in probabilistic AI and foremost expert in Bayesian deep learning and Generative AI
University College London (UCL), OSIC Computational Science Lead
  • Discussion Points
  • Predictive power: Could interpretable survival models predict disease progression and patient outcomes than traditional methods?

  • Interpretability at the core: Attention maps that show which lung regions drive predictions, helping clinicians trust results

  • Cross-disease potential: Can be applied across fibrotic ILDs, bronchiectasis, and post-COVID fibrosis to build a multi-disease model

Unlocking Innovation: Exploring New Features and Advanced Filters in the OSIC Cloud

  • Presenter
Sandra Stapleton
Sandra Stapleton Chief Operating Officer
VIDA Diagnostics
  • Discussion Points
  • Overview of the latest enhancements to the OSIC Cloud platform, and how these features streamline data access and accelerate research workflows

  • Demonstration of how new imaging filters and views, including tMPR and subpleural views, improve data visualization and analysis

  • Exploration of the new collaboration tool designed for private cohort development

  • Presentation of the live analytics dashboard for real-time insights

Turning Data Into Discovery:
The Achievements of OSIC Members with the OSIC Cloud’s Powerful Data

From core lab to clinic: improving patient care with AI imaging biomarkers

  • Presenter
Dr. George Harston
Dr. George Harston Chief Medical and Innovation Officer
Brainomix
  • Discussion Points
  • Validation of algorithm performance and generalisability

     

  • Demonstration of value and maximising impact

     

  • Patient impact through clinical development and clinical adoption

When virtual OSIC database becomes virtuOSIC

  • Presenter
Dr. Ryoungwoo Jang
Dr. Ryoungwoo Jang Clinical Research Lead
Coreline Soft
  • Discussion Points
  • The OSIC database was instrumental in developing an estimated FVC (eFVC) metric that can be calculated from chest HRCT scans.

  • eFVC mimics real FVC measurements, demonstrating a high correlation validated in the separate cohort.

     

  • eFVC shows promise as a tool for monitoring disease status, predicting progression, and assessing response to pharmaceutical treatments.

AI-Based Quantification of Airway Diseases: From Comprehensive Characterization to Phenotyping and Progression Tracking

  • Presenter
Dr. Jean-Paul Charbonnier
Dr. Jean-Paul Charbonnier Chief Innovation Officer
Thirona
  • Discussion Points
  • How can AI-based quantification of airway wall thickening, mucus plugging, and bronchiectasis provide meaningful patient phenotypes?

  • Could longitudinal tracking of AI-based airway quantification provide more precise disease trajectory assessment?

  • What value does this bring to patient stratification and measuring treatment response?

SEPI-IA: A Spanish, Publicly Funded Research Initiative

  • Presenter
Carlos Illana Alejandro
Carlos Illana Alejandro Head of Advanced Health Products, PRO, Secure eSolutions
GMV
  • Discussion Points
  • What are the objectives of SEPI-IA?

  • Who is the team behind SEPI-IA?

Member Meeting Replay

If you weren’t able to attend, or would like to revisit a presentation, recordings will be made available to members when ready.